Cargando…

PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane

PURPOSE: Everolimus plus exemestane (EVE/EXE) is a registered treatment option for ER-positive, HER2-negative (ER +/HER2-) metastatic breast cancer (MBC), but resistance mechanisms limit efficacy. We aimed to find markers that might help select patients with a higher chance on benefit from EVE/EXE....

Descripción completa

Detalles Bibliográficos
Autores principales:	Kruger, Dinja T., Opdam, Mark, van der Noort, Vincent, Sanders, Joyce, Nieuwenhuis, Michiel, de Valk, Bart, Beelen, Karin J., Linn, Sabine C., Boven, Epie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Article – Clinical Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519923/ https://www.ncbi.nlm.nih.gov/pubmed/32566979 http://dx.doi.org/10.1007/s00432-020-03291-x

Ejemplares similares

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
por: Kruger, Dinja T., et al.
Publicado: (2018)

Hierarchical clustering of PI3K and MAPK pathway proteins in breast cancer intrinsic subtypes
por: Kruger, Dinja T., et al.
Publicado: (2020)

IGF‐1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER‐positive breast cancer
por: Kruger, Dinja T., et al.
Publicado: (2019)

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane
por: Kruger, Dinja T., et al.
Publicado: (2020)

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes
por: Sobral-Leite, Marcelo, et al.
Publicado: (2019)

Prospective Study of Drug-induced Interstitial Lung Disease in Advanced Breast Cancer Patients Receiving Everolimus Plus Exemestane
por: Willemsen, Annelieke E. C. A. B., et al.
Publicado: (2019)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
por: Lee, Kyoungmin, et al.
Publicado: (2022)

PI3K/AKT/mTOR pathway activation in primary and corresponding metastatic breast tumors after adjuvant endocrine therapy
por: Beelen, Karin, et al.
Publicado: (2014)

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
por: Schmid, Peter, et al.
Publicado: (2023)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot
por: Beelen, Karin, et al.
Publicado: (2018)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2013)

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2014)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
por: Rozenblit, Mariya, et al.
Publicado: (2021)

Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
por: Nakatsukasa, Katsuhiko, et al.
Publicado: (2021)

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial
por: Hadji, Peyman, et al.
Publicado: (2018)

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
por: Cazzaniga, Marina, et al.
Publicado: (2018)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

A Case of Disease Improvement after Treatment with Everolimus plus Exemestane in a Patient with Hormone Receptor-Positive Metastatic Breast Cancer with Bone Metastases
por: Beck, J. Thaddeus, et al.
Publicado: (2015)

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
por: Cazzaniga, Marina, et al.
Publicado: (2018)

Comparative Treatment Patterns and Outcomes of Fulvestrant versus Everolimus Plus Exemestane for Postmenopausal Metastatic Breast Cancer Resistant to Aromatase Inhibitors in Real-World Experience
por: Li, Yi, et al.
Publicado: (2020)

Case report: 5-year progression free survival and complete liver response in a patient with metastatic breast cancer treated with everolimus plus exemestane
por: Krasniqi, Eriseld, et al.
Publicado: (2020)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study
por: Kourlaba, Georgia, et al.
Publicado: (2015)

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study
por: Cazzaniga, Marina, et al.
Publicado: (2018)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Clinical utility of exemestane in the treatment of breast cancer
por: Zucchini, Giorgia, et al.
Publicado: (2015)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer
por: Bhin, Jinhyuk, et al.
Publicado: (2023)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

A review of the use of exemestane in early breast cancer
por: Robinson, Andrew
Publicado: (2009)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_o0j56grmprvp1h5alfv2fm7jvo